Immunocore Holdings Stock Analysis

IMCR Stock  USD 29.64  0.17  0.57%   
Immunocore Holdings is undervalued with Real Value of 37.68 and Target Price of 60.91. The main objective of Immunocore Holdings stock analysis is to determine its intrinsic value, which is an estimate of what Immunocore Holdings is worth, separate from its market price. There are two main types of Immunocore Holdings' stock analysis: fundamental analysis and technical analysis.
The Immunocore Holdings stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Immunocore Holdings is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Immunocore Stock trading window is adjusted to America/New York timezone.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunocore Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.

Immunocore Stock Analysis Notes

About 94.0% of the company shares are owned by institutional investors. The book value of Immunocore Holdings was currently reported as 7.21. The company recorded a loss per share of 1.02. Immunocore Holdings had not issued any dividends in recent years. Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Immunocore Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 324 people. To learn more about Immunocore Holdings call Bahija Jallal at 44 12 3543 8600 or check out https://www.immunocore.com.

Immunocore Holdings Quarterly Total Revenue

84.05 Million

Immunocore Holdings Investment Alerts

The company reported the previous year's revenue of 310.2 M. Net Loss for the year was (51.09 M) with profit before overhead, payroll, taxes, and interest of 299.7 M.
Immunocore Holdings has a poor financial position based on the latest SEC disclosures
Over 94.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: Immunocore Moves 6.0 percent Higher Will This Strength Last

Immunocore Holdings Upcoming and Recent Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Immunocore Largest EPS Surprises

Earnings surprises can significantly impact Immunocore Holdings' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-12
2021-03-31-0.83-0.92-0.0910 
2025-05-06
2025-03-31-0.36-0.49-0.1336 
2024-05-08
2024-03-31-0.36-0.49-0.1336 
View All Earnings Estimates

Immunocore Holdings Environmental, Social, and Governance (ESG) Scores

Immunocore Holdings' ESG score is a quantitative measure that evaluates Immunocore Holdings' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Immunocore Holdings' operations that may have significant financial implications and affect Immunocore Holdings' stock price as well as guide investors towards more socially responsible investments.

Immunocore Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Armistice Capital, Llc2024-12-31
1.2 M
Fiera Capital Corporation2024-12-31
780 K
Citigroup Inc2024-12-31
632.9 K
Two Sigma Advisers, Llc2024-12-31
604.9 K
Groupama Asset Management2024-12-31
600 K
Millennium Management Llc2024-12-31
573.4 K
Deep Track Capital, Lp2024-12-31
519.4 K
Principal Financial Group Inc2024-12-31
502.9 K
Massachusetts Financial Services Company2024-12-31
459 K
T. Rowe Price Investment Management,inc.2024-12-31
6.7 M
Wellington Management Company Llp2024-12-31
6.6 M
Note, although Immunocore Holdings' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunocore Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.49 B.

Immunocore Profitablity

The company has Profit Margin (PM) of (0.16) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.02.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.05)(0.05)
Return On Capital Employed(0.09)(0.09)
Return On Assets(0.05)(0.05)
Return On Equity(0.14)(0.15)

Management Efficiency

Immunocore Holdings has return on total asset (ROA) of (0.0408) % which means that it has lost $0.0408 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1401) %, meaning that it created substantial loss on money invested by shareholders. Immunocore Holdings' management efficiency ratios could be used to measure how well Immunocore Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/24/2025, Return On Tangible Assets is likely to drop to -0.05. In addition to that, Return On Capital Employed is likely to drop to -0.09. At this time, Immunocore Holdings' Net Tangible Assets are relatively stable compared to the past year. As of 03/24/2025, Total Current Assets is likely to grow to about 976.4 M, while Other Current Assets are likely to drop slightly above 24.2 M.
Last ReportedProjected for Next Year
Book Value Per Share 7.22  7.58 
Tangible Book Value Per Share 7.22  7.58 
Enterprise Value Over EBITDA(15.05)(15.81)
Price Book Value Ratio 4.09  3.88 
Enterprise Value Multiple(15.05)(15.81)
Price Fair Value 4.09  3.88 
Enterprise Value2.7 B2.8 B
Immunocore Holdings showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Operating Margin
(0.02)
Profit Margin
(0.16)
Beta
0.796
Return On Assets
(0.04)
Return On Equity
(0.14)

Technical Drivers

As of the 24th of March, Immunocore Holdings retains the Risk Adjusted Performance of 0.0337, downside deviation of 2.65, and Market Risk Adjusted Performance of 0.1469. Immunocore Holdings technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Immunocore Holdings coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Immunocore Holdings is priced fairly, providing market reflects its last-minute price of 29.64 per share. Given that Immunocore Holdings has jensen alpha of 0.1074, we strongly advise you to confirm Immunocore Holdings's regular market performance to make sure the company can sustain itself at a future point.

Immunocore Holdings Price Movement Analysis

Execute Study
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Immunocore Holdings middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Immunocore Holdings. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Immunocore Holdings Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunocore Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunocore Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunocore Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Baker Bros. Advisors Lp six days ago
Disposition of tradable shares by Baker Bros. Advisors Lp of Immunocore Holdings subject to Rule 16b-3
 
Travis Coy over two months ago
Acquisition by Travis Coy of 274033 shares of Immunocore Holdings at 29.5 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over three months ago
Discretionary transaction by Baker Bros. Advisors Lp of 674261 shares of Immunocore Holdings subject to Rule 16b-3
 
Baker Bros. Advisors Lp over three months ago
Discretionary transaction by Baker Bros. Advisors Lp of 674261 shares of Immunocore Holdings subject to Rule 16b-3
 
Herbst Roy Steven over six months ago
Disposition of 8676 shares by Herbst Roy Steven of Immunocore Holdings at 58.69 subject to Rule 16b-3
 
Berman David M over six months ago
Disposition of 28553 shares by Berman David M of Immunocore Holdings at 17.46 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over six months ago
Discretionary transaction by Baker Bros. Advisors Lp of 1449226 shares of Immunocore Holdings subject to Rule 16b-3
 
Bell John Irving over six months ago
Acquisition by Bell John Irving of 14534 shares of Immunocore Holdings at 50.47 subject to Rule 16b-3
 
St Leger Tina Amber over six months ago
Disposition of 4375 shares by St Leger Tina Amber of Immunocore Holdings at 64.06 subject to Rule 16b-3
 
Bahija Jallal over a year ago
Acquisition by Bahija Jallal of 281819 shares of Immunocore Holdings at 70.5 subject to Rule 16b-3
 
Bell John Irving over a year ago
Immunocore Holdings exotic insider transaction detected

Immunocore Holdings Outstanding Bonds

Immunocore Holdings issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunocore Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunocore bonds can be classified according to their maturity, which is the date when Immunocore Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Immunocore Holdings Predictive Daily Indicators

Immunocore Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunocore Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Immunocore Holdings Corporate Filings

F4
19th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
17th of March 2025
Other Reports
ViewVerify
8K
10th of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F3
27th of February 2025
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
10K
26th of February 2025
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
F4
19th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
14th of February 2025
Other Reports
ViewVerify
13th of February 2025
Other Reports
ViewVerify

Immunocore Holdings Forecast Models

Immunocore Holdings' time-series forecasting models are one of many Immunocore Holdings' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunocore Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Immunocore Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunocore Holdings prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunocore shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunocore Holdings. By using and applying Immunocore Stock analysis, traders can create a robust methodology for identifying Immunocore entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.17)(0.18)
Operating Profit Margin(0.23)(0.24)
Net Loss(0.16)(0.17)
Gross Profit Margin 0.99  1.04 

Current Immunocore Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunocore analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunocore analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
60.91Strong Buy15Odds
Immunocore Holdings current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Immunocore analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunocore stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunocore Holdings, talking to its executives and customers, or listening to Immunocore conference calls.
Immunocore Analyst Advice Details

Immunocore Stock Analysis Indicators

Immunocore Holdings stock analysis indicators help investors evaluate how Immunocore Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunocore Holdings shares will generate the highest return on investment. By understating and applying Immunocore Holdings stock analysis, traders can identify Immunocore Holdings position entry and exit signals to maximize returns.
Begin Period Cash Flow442.6 M
Long Term Debt391 M
Common Stock Shares Outstanding50 M
Total Stockholder Equity360.7 M
Tax Provision-1.9 M
Quarterly Earnings Growth Y O Y8.22
Property Plant And Equipment Net47.7 M
Cash And Short Term Investments820.4 M
Cash455.7 M
Accounts Payable25.1 M
Net Debt-414 M
50 Day M A30.0326
Total Current Liabilities212.2 M
Other Operating Expenses380.7 M
Non Current Assets Total79.6 M
Non Currrent Assets Other17.1 M
Stock Based Compensation34.2 M

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.